Randomized Controlled Trial of the Efficacy of ProGenX in the Resolution of Post-COVID Fatigue & Immune status

ihar Ranjan Pradhan0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•Males or non-pregnant, non-lactating females aged - 18 to 75 years (both inclusive);
•RT-PCR confirmed diagnosis of COVID-19 at any time followed by an RT-PCR negative test;
•Patients experiencing fatigue and muscle weakness;
•Able to take the drug orally and comply with study procedures;
•Women of childbearing potential with a negative urine pregnancy test.

•Prior known respiratory distress (RR-30 times/min);
•Finger oxygen saturation < 90% in a resting state,
•Arterial partial pressure of oxygen(pao2)/concentration of oxygen inhalation (Fio2) <300 mmHg;
•Respiratory failure or on mechanical ventilation,
•ICU needed for other organ failure;
•Patients with other viral pneumonia;
•Patients unable to take food or drugs due to coma or intestinal obstruction;
•Consumption of other oral probiotic supplements during the trial;
•Patients with severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected;
•Blood diseases
•Active bleeding
•Severe malnutrition
•Women who are pregnant or lactating
•Subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period;
•Patients allergic to systemic enzyme supplements;
•Patients facing imminent death in the opinion of the clinical team;
•Patients with Hb less than 10 g/dl;
•Patients who have participated in any other clinical study within 2 weeks prior to randomization

发起方

ihar Ranjan Pradhan